Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

Pediatrics
D K KelseyAlbert J Allen

Abstract

Atomoxetine seems to be as effective for treating attention-deficit/hyperactivity disorder (ADHD) when the daily dose is administered once in the morning as when the dose is divided and administered in the morning and evening. In the present study, the efficacy of atomoxetine administered once daily among children with ADHD was assessed throughout the day, including the evening and early morning. Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms. This study was a randomized, multicenter, double-blind, placebo-controlled trial conducted at 12 outpatient sites in the United States. A total of 197 children, 6 to 12 years of age, who had been diagnosed as having ADHD, on the basis of the Diagnostic and Statistical Manual of Mental Disorders (4th ed.) criteria, were randomized to receive 8 weeks of treatment with atomoxetine or placebo, dosed once daily in the mornings. ADHD symptoms were assessed with parent and investigator rating scales. The primary outcome measure was the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored total score. Daily parent assessments of children's home behaviors in the ...Continue Reading

References

May 1, 1991·Journal of the American Academy of Child and Adolescent Psychiatry·R G Klein, S Mannuzza
May 20, 1998·The American Journal of Psychiatry·T SpencerL Seidman
Dec 11, 1999·Archives of Pediatrics & Adolescent Medicine·M A KentP R Camfield
Feb 24, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·L L GreenhillT Wigal

❮ Previous
Next ❯

Citations

May 9, 2006·European Child & Adolescent Psychiatry·Tobias BanaschewskiEric Taylor
Feb 8, 2008·European Child & Adolescent Psychiatry·Yann PoncinLawrence Scahill
Dec 8, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Peter M WehmeierUlrike Ravens-Sieberer
Mar 25, 2011·Attention Deficit and Hyperactivity Disorders·Peter M WehmeierTobias Banaschewski
Apr 24, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nicolas RamozPhilip Gorwood
Jan 14, 2005·The New England Journal of Medicine·Marsha D Rappley
Dec 29, 2005·Journal of Child and Adolescent Psychopharmacology·Mina Hah, Kiki Chang
Jan 5, 2007·Journal of Child and Adolescent Psychopharmacology·Calvin R SumnerDouglas K Kelsey
Sep 8, 2007·Journal of Child and Adolescent Psychopharmacology·UNKNOWN Atomoxetine ADHD and Comorbid MDD Study GroupCalvin R Sumner
Dec 29, 2009·Journal of Child and Adolescent Psychopharmacology·Michel MaziadeRuth Dickson
Apr 15, 2009·Journal of Child and Adolescent Psychopharmacology·Jaswinder K GhumanCarolyn Fort
Dec 29, 2009·Journal of Child and Adolescent Psychopharmacology·Linda A WietechaKory Schuh
Jun 29, 2010·Journal of Child and Adolescent Psychopharmacology·Nakia Gray ScottDean Kjar
Feb 16, 2007·The Journal of Perinatal & Neonatal Nursing·Aletta E Harres
Feb 5, 2011·Menopause : the Journal of the North American Menopause Society·C Neill EppersonThomas E Brown
Sep 6, 2011·Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine·Margot PutukianRussell D White
Jul 3, 2009·International Journal of Clinical Practice·S PrasadS E Libretto
Sep 17, 2008·Child and Adolescent Psychiatry and Mental Health·Christopher J KratochvilLaurence L Greenhill
Aug 26, 2009·Child and Adolescent Psychiatry and Mental Health·Ralf W DittmannGerd Lehmkuhl
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Paul HammernessDaniel Geller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.